{
  "abstract": "Cystic fibrosis (CF) has been transformed by therapies that correct and potentiate the cystic fibrosis transmembrane conductance regulator (CFTR) protein.1 Highly effective CFTR modulator therapies are now available for >90% of patients with CF in many countries, including the UK.2 This has hugely improved lung function and stabilised a condition previously characterised by progressive bronchiectasis, lung function decline and premature death. The majority of young people entering adult care now have spirometry within the normal range.3",
  "authors": [
    {
      "affiliations": [
        "Manchester Adult Cystic Fibrosis Center, Manchester University NHS Foundation Trust, Manchester, UK",
        "Division of Immunology, Immunity to Infection and Respiratory Medicine, The University of Manchester, Manchester, UK"
      ],
      "name": "Alex Robert Horsley"
    },
    {
      "affiliations": [
        "POLARIS, School of Medicine and Population Health, University of Sheffield, Sheffield, UK",
        "The University of Sheffield Insigneo Institute for in silico Medicine, Sheffield, UK"
      ],
      "name": "Jim M Wild"
    }
  ],
  "title": "Changing face of lung monitoring in CF: from tracking decline to maintaining healthy lungs",
  "uid": "76fe505d-daf9-5cef-bd12-701ca5fecd59"
}